Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.
about
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its ComorbiditiesImmune dysfunction in uremia—an updateMetabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological settingThe systemic nature of CKD.The uraemic toxin phenylacetic acid contributes to inflammation by priming polymorphonuclear leucocytes.Gut microbiome and kidney disease: a bidirectional relationship.Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells.Combining Hydrophilic Interaction Chromatography (HILIC) and Isotope Tagging for Off-Line LC-NMR Applications in Metabolite Analysis.Biochemical and clinical evidence for uremic toxicity.Dietary protein restriction benefits patients with chronic kidney disease.The epidemic of cardio-vascular disease in renal failure: where does it come from, where do we go?Protein-bound toxins--update 2009.Platelet/Leukocyte activation, inflammation, and uremia.Update of uremic toxin research by mass spectrometry.Normal and pathologic concentrations of uremic toxins.The vulnerable patient with chronic kidney disease.The intestine and the kidneys: a bad marriage can be hazardous.Gas Chromatography/Mass Spectrometry Metabolomics of Urine and Serum from Nonhuman Primates Exposed to Ionizing Radiation: Impacts on the Tricarboxylic Acid Cycle and Protein Metabolism.Adsorption capacity of poly(ether imide) microparticles to uremic toxins.Interaction of human serum albumin with short polyelectrolytes: a study by calorimetry and computer simulations.Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency.Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation.Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption.Modulation of NADPH oxidase activity by known uraemic retention solutes.Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Chronic NOS inhibition actuates endothelial-mesenchymal transformation.Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique.
P2860
Q26798487-2DC68486-3BC3-41E4-8D54-0D6E68D065E1Q26829076-E8A42F65-7317-4CEA-9B29-21CE6248B06CQ28748492-0CA3DEC1-EE19-449D-AEB6-D6C67ABC7DFDQ30234695-69C4837E-4325-432F-A207-15B54D89B6E1Q31108601-33D6CF5E-13D5-4B2E-B8DD-41605B14F27AQ33586234-029A3295-54D7-4E3F-A619-D244F7A4D8AFQ33869303-21916312-5140-4961-BB29-3F76164ABA65Q35032235-07FE526E-BD8F-4854-97F3-B64A402399B4Q35173890-611236BE-F589-4EF9-BD49-4409C54DD3C8Q35717674-8ECE3D58-8813-498E-93C9-F5939BFC58EEQ36410512-40C1B937-15E1-42EC-890D-815997780942Q36714285-6C1B0CEE-DC9E-4FC5-98C0-49C2B58236A6Q37587272-C781CE46-B43F-4297-AE48-BDEC0255583BQ37587321-53048627-941F-4F26-9512-12DD32D4AE4AQ37844014-56486FA5-7162-4686-B515-925F1A332D3AQ38012908-D90C9F6E-7BED-43BB-8F7D-4B3EDEB3B73EQ38368207-7942541B-A952-4987-ABC0-F2E9D4170FEDQ38393212-964D196E-F1B2-4315-B0D6-C4462C49BA03Q38870782-7B5D50AC-5F6D-4819-9411-DEB95AAA0817Q38934983-547D78B4-D9B4-4459-9A41-A28948EC61D7Q40955319-DBB88434-CCEA-4810-854F-EB718E8FFA98Q44792825-C244C968-31B3-43B7-A622-5A63D261264CQ44796931-DC560BC7-DE80-4198-B0FB-CFB0572DBA8EQ46803998-6FBB7588-FB45-4F82-91E6-BA015EF28CB9Q46864424-510F084F-6E04-4636-99DD-B435D1DB7E98Q47216784-AA7576AB-D4F8-4974-83A1-00A07AC17FC5Q50715902-2C36D2FD-6E76-425F-AF0D-59D60B5ED4A0Q52885182-80C0D0CA-179E-443D-B54B-4CD2BE42CC21
P2860
Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@ast
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@en
type
label
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@ast
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@en
prefLabel
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@ast
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@en
P2093
P2860
P356
P1476
Increased plasma phenylacetic ...... lure inhibits iNOS expression.
@en
P2093
H Luftmann
H Schluter
J Jankowski
M van der Giet
P2860
P304
P356
10.1172/JCI200315524
P407
P577
2003-07-01T00:00:00Z